Protalix BioTherapeutics, Inc. (NYSEMKT:PLX)

CAPS Rating: 2 out of 5

A clinical stage biopharmaceutical company that is focused on developing and manufacturing recombinant therapeutic proteins that are produced through its proprietary plant cell system.

Recs

0
Player Avatar pchop123 (76.56) Submitted: 8/17/2012 4:20:07 PM : Outperform Start Price: $5.38 PLX Score: -5.02

disruptive technology that could be a substantial winner in the near term

Featured Broker Partners


Advertisement